Beam Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held by Beam Therapeutics Inc. on June 4, 2025. The filing details the voting outcomes for director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Proposal 1 (Director Elections): All three Class II director nominees were elected to serve until the 2028 annual meeting.
- Mark Fishman, M.D.: 61,949,019 For; 10,285,110 Against; 63,755 Abstentions.
- Carole Ho, M.D.: 71,720,651 For; 548,021 Against; 29,212 Abstentions.
- Kathleen Walsh: 71,888,413 For; 379,636 Against; 29,835 Abstentions.
- Proposal 2 (Auditor Ratification): The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
- Votes: 84,281,031 For; 154,426 Against; 63,599 Abstentions.
- Proposal 3 (Executive Compensation): The compensation of named executive officers was approved on an advisory basis.
- Votes: 71,701,062 For; 562,871 Against; 33,951 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares entitled to vote versus the total votes cast to assess shareholder participation rates.
- Review the "Against" vote count for Mark Fishman, M.D., which was significantly higher than for the other nominees (approx. 14.3% of votes cast excluding abstentions).
- Confirm the term end date for the newly elected directors is the 2028 annual meeting.
- Check the Definitive Proxy Statement filed on April 18, 2025, for detailed background on the director nominees and compensation rationale.